SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is trending as the community debates its long-term potential amid the broader push for tokenization and regulatory clarity. Investors are actively discussing the project's role as critical infrastructure for bridging real-world data to blockchain networks while monitoring technical price levels.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is facing intense volatility following a mixed earnings report that missed revenue and EPS targets, despite a significant backlog expansion. The community is sharply divided between retail bulls who are leveraging the dip to accumulate, and skeptical traders who are concerned about execution delays, cash burn, and future dilution.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is facing significant downward pressure, with community sentiment deeply polarized as the asset struggles to maintain the psychological support level of one dollar. Investors are actively debating whether the current price represents a long-term accumulation opportunity or if ongoing concerns regarding dilution and regulatory delays signify a deeper capitulation phase.

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is seeing heavy volatility and significant institutional interest as traders speculate on upcoming Phase 3 trial results for its wet AMD treatment. The community is actively debating the potential for a short squeeze given high short interest, while analysts remain focused on the pivotal data readout as the primary catalyst for the stock's next major move.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop shares are seeing a notable boost, with the community actively debating whether the rally is driven by strong underlying growth and a unique asset-light business model or if the stock is overextended ahead of earnings. Investors remain divided between long-term confidence in the company's aggressive unit expansion and short-term skepticism regarding the impact of cooling consumer demand on same-store sales.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

MSTX is seeing intense community debate as traders weigh the risks of significant volatility decay against the potential for an explosive rebound tied to MicroStrategy and Bitcoin performance. While many participants view the current depressed price levels as a bargain-hunting opportunity for massive gains, others are warning of the dangers of leveraged ETFs, specifically highlighting the threat of reverse splits and long-term value erosion.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is experiencing significant price volatility as investors weigh a wave of institutional profit-taking and technical noise against strong long-term AI-driven fundamentals. The community remains divided between those capitalizing on the dip as a tactical buying opportunity and those concerned about short-term market manipulation and high valuation multiples.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines is surging as investors react to new U.S. government drone tariff policies aimed at strengthening domestic supply chains and reducing dependence on foreign imports. The stock is seeing heavy retail and institutional interest, with the community actively debating whether the companys role as an upstream component manufacturer justifies its high valuation and current momentum.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance is trending as investors react to a confirmed breakout above recent resistance levels, with strong community excitement focused on the stock's potential for a short squeeze and upcoming clinical catalysts. The conversation is largely centered on the company's expanding oncology platform, with many retail participants discussing the long-term potential for institutional re-rating and pipeline milestones in lung cancer and other solid tumors.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is experiencing significant volatility and heavy trading volume as the community debates its long-term viability following a major bridge security breach. While some investors view the current price action as a strategic accumulation opportunity for this privacy-focused asset, others remain skeptical, citing concerns over developer communication and the impact of the ongoing token unlock schedule.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'

PTC Therapeutics plans to acquire Sangamo's ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.read more...

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program PR Newswire WARREN, N.J., Aug. 12, 2026 Planned acquisition leverages existing regulatory and commercial...

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +641.18% and +22.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results PR Newswire WARREN, N.J., July 30, 2026 Robust Q2 performance with total revenue of $361 million, including $239...

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hamilton Lane Board Elects Michael Schmertzler as New Independent Director

Hamilton Lane Board Elects Michael Schmertzler as New Independent Director Hamilton Lane Board Elects Michael Schmertzler as New Independent Director PR Newswire CONSHOHOCKEN, Pa., July 23, 2026 CONSHOHOCKEN, Pa., July 23, 2026 /PRNewswire/ -- Leading private markets investment management firm...

uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix

QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

PTC Therapeutics Inc

PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided

Equity

Bullish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$71.70
Prev Close	$71.97
Open	$71.58
Dividend Yield	0.00%
50-Day Moving Average	$77.37
Beta	1.11
Avg. Volume	1.72M
PE Ratio	-120.75

52-Week High	$90.87
52-Week Low	$47.94
Market Capitalization	$6.01B
EPS (Annual)	$7.78
Price to Book	-36.13
Revenue Per Employee	$1.75M

Feed

News

Sentiment

Earnings

Fundamentals

Info